PASSAGE BIO, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
PASSAGE BIO, INC. (PASG) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $3.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-04.
Discontinued › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-03-04
- PASSAGE BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- PASSAGE BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-09-30 was $1.50M, a 72.73% decline year-over-year.
- PASSAGE BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-06-30 was $0.00.
- PASSAGE BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-03-31 was $1.50M, a 0.00% change year-over-year.
- PASSAGE BIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $3.00M, a 62.50% decline from fiscal 2021.
- PASSAGE BIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2021 was $8.00M, a 700.00% increase from fiscal 2020.
- PASSAGE BIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2020 was $1.00M, a 100.00% increase from fiscal 2019.
- PASSAGE BIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2019 was $500.00K.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $1.50M derived: sum of 2 quarters · filed 2024-03-04 | $1.50M derived: sum of 3 quarters · filed 2024-03-04 | $3.00M 10-K · filed 2024-03-04 |
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-13 | $1.50M derived: sum of 2 quarters · filed 2023-11-13 | $3.00M 10-Q · filed 2023-11-13 | $4.00M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.50M 10-Q · filed 2023-08-07 | $2.50M derived: sum of 3 quarters · filed 2023-08-07 | $8.00M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $1.50M 10-Q · filed 2023-05-11 | $2.50M derived: sum of 2 quarters · filed 2023-05-11 | $8.00M derived: sum of 3 quarters · filed 2023-05-11 | $8.00M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $6.50M derived: sum of 2 quarters · filed 2023-03-06 | $6.50M derived: sum of 3 quarters · filed 2023-03-06 | $8.00M 10-K · filed 2023-03-06 |
| 2021-09-30 | $5.50M 10-Q · filed 2022-11-10 | $5.50M derived: sum of 2 quarters · filed 2022-11-10 | $7.00M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.50M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $1.50M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $1.00M 10-K · filed 2022-03-03 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $0.00 derived: sum of 2 quarters · filed 2021-03-03 | $500.00K derived: sum of 3 quarters · filed 2021-03-03 | $500.00K 10-K · filed 2021-03-03 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $500.00K derived: sum of 2 quarters · filed 2020-11-10 | $500.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $500.00K 10-Q · filed 2020-08-13 | $500.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |